Structure Therapeutics, Inc.
https://structuretx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Structure Therapeutics, Inc.
Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity
Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Structure Therapeutics Aims For Best-In-Class Oral Incretin
Phase II data are positive but early, and drawing any big conclusions might be premature.
IPOs Fizzle Out In The Fourth Quarter
Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- ADMET
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Basecamp Bio
- Shanghai ShouTi Biotechnology Co. Ltd.
- ShouTi, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice